A First Look at BioCentriq™

Choose New Jersey is hosting the first of what they plan to be a series of live webinars entitled “New Jersey: A Rising Cell & Gene Therapy Hub.” The first session will be a virtual premiere of BioCentriq™, our new state-of-the-art cell and gene therapy development center.

Be among the first to tour this brand new industry-facing contract development and manufacturing organization (CDMO) dedicated to cell and gene therapies. Located in Newark, NJ on the campus of NJIT, BioCentriq™ features GMP suites for clinical production of cell & gene therapies and a process development pilot plant. The center is poised to attract global leaders in the biopharmaceutical industry as well as promising start-ups, which will develop new and innovative therapies.

The agenda includes:

Opening Remarks

  • President Dr. Joel Bloom, NJIT
  • Robert Cohen, President, Digital, Robotics, and Enabling Technology, Stryker
  • Simon Nynens, CEO, NJII
  • Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)

Ribbon Cutting & Virtual Tour of BioCentriq™

  • Dr. Haro Hartounian, SVP and General Manager, NJII Biopharma Division

Panel: The Keys to the Future of Cell & Gene Therapy Manufacturing

Moderator: Dr. Haro Hartounian, SVP and General Manager, NJII Biopharma Division

  • Janet Lynch Lambert, CEO of Alliance for Regenerative Medicine
  • Kelvin Lee, Director, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
  • Greg Russotti, Ph.D. Chief Technology Officer Century Therapeutics, LLC

Panel: Why Choose New Jersey for Cell & Gene Therapy

  • Kevin D. Belfield, Dean, College of Science & Liberal Arts, NJIT
  • Debbie Hart, President & CEO, BioNJ
  • Jose Lozano, President & CEO, Choose New Jersey
  • Kathleen Coviello, Executive Vice President for Technology, Life Sciences & Entrepreneurship, New Jersey Economic Development Authority (NJEDA)